Cargando…
The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma
Proteasome inhibitors have provided a significant advance in the treatment of multiple myeloma (MM). Consequently, there is increasing interest in developing strategies to target E3 ligases, de-ubiquitinases, and/or ubiquitin receptors within the ubiquitin proteasome pathway, with an aim to achieve...
Autores principales: | Crawford, Lisa J., Campbell, David C., Morgan, Jonathan J., Lawson, Michelle A., Down, Jennifer M., Chauhan, Dharminder, McAvera, Roisin M., Morris, Treen C., Hamilton, Claudia, Krishnan, Aswini, Rajalingam, Krishnaraj, Chantry, Andrew D., Irvine, Alexandra E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329634/ https://www.ncbi.nlm.nih.gov/pubmed/32523091 http://dx.doi.org/10.1038/s41388-020-1345-x |
Ejemplares similares
-
TRAF6 Silencing Attenuates Multiple Myeloma Cell Adhesion to Bone Marrow Stromal Cells
por: Morgan, Jonathan J., et al.
Publicado: (2019) -
Genetic Abnormalities in Extramedullary Multiple Myeloma
por: McAvera, Roisin, et al.
Publicado: (2023) -
TIF1 Proteins in Genome Stability and Cancer
por: McAvera, Roisin M., et al.
Publicado: (2020) -
Tipping the MYC–MIZ1 balance: targeting the HUWE1 ubiquitin ligase selectively
blocks MYC-activated genes
por: Schaub, Franz X, et al.
Publicado: (2014) -
Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the
HUWE1 ubiquitin ligase
por: Peter, Stefanie, et al.
Publicado: (2014)